Executive Transaction Details
Anthony Bergmann, serving as the Chief Financial Officer for Capricor Therapeutics, Inc. (NASDAQ: CAPR), completed the sale of 900 shares of the company's common stock. The total value of these transactions amounted to $27,000. The shares were divested at a uniform price of $30.00 per share across two distinct dates, June 22 and June 24, 2026.
The disposition of these shares was directly preceded by the acquisition of an equivalent number of common shares through the exercise of stock options. Mr. Bergmann acquired these 900 common shares at an exercise price of $3.18 per share, resulting in a total cost of $2,862. The underlying options, which grant the holder the right to purchase common stock, follow a specific vesting schedule. These shares vested at a rate of 1/48th on the first day of each month, beginning on February 1, 2022. The options are contracted to expire in January 2032.
The sales were carried out in accordance with a 10b5-1 trading plan that Mr. Bergmann established in December 2025. Following the completion of these transactions, Mr. Bergmann maintains direct ownership of 11,223 shares of Capricor Therapeutics common stock. Additionally, he holds 116,080 derivative shares in the form of stock options.
Corporate Financial and Regulatory Context
Recent corporate developments for Capricor Therapeutics indicate a period of active financial and regulatory engagement. The company reported a first-quarter loss for 2026 that exceeded analyst expectations. Earnings per share (EPS) were recorded at -$0.59, compared to the forecasted figure of -$0.52.
Despite the larger-than-expected loss, the company provided assurance regarding its liquidity position. Capricor stated that it possesses sufficient cash reserves to sustain operations through the fourth quarter of 2027. This financial runway is critical as the firm navigates the review process for its lead product, Deramiocel. The FDA is currently conducting an active review, with a Prescription Drug User Fee Act (PDUFA) date established for August 22, 2026.
Further corporate actions include the filing of a rescission against Nippon Shinyaku and NS Pharma. Market sentiment toward the stock remains positive among certain analysts, with B.Riley reiterating a Buy rating and maintaining a price target of $63.
Market Data Snapshot
Trading activity for Capricor Therapeutics reflects recent market fluctuations. The stock closed at $29.51, representing a decline of $0.09 or 0.30%. After-hours trading saw the price move to $29.29, a decrease of $0.218 or 0.74%.